Business
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
PLYMOUTH MEETING, Pa., February 24, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4113,"height":1051,"url":"https://media.zenfs.com/en/business-wire.com/5e40b39f01f8ad3a89d698e2c883cbc6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PiFz2ijD9FdZ4vkIGGILww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5e40b39f01f8ad3a89d698e2c883cbc6","width":960,"height":245},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/wW58iTCn8qOK4iavTwgnVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5e40b39f01f8ad3a89d698e2c883cbc6","width":1200,"height":307}},"lazy":false},{"type":"text","content":"WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy","length":143,"tagName":"p","attribs":{}},{"type":"text","content":"Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise","length":103,"tagName":"p","attribs":{}},{"type":"text","content":"Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s","length":98,"tagName":"p","attribs":{}},{"type":"text","content":"Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"Potential Best-In-Class Orexin-2 Agonist (BP1.15205) Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"Conference Call and Webcast Today at 8:30 a.m. ET","length":49,"tagName":"p","attribs":{}},{"type":"text","content":"PLYMOUTH MEETING, Pa., February 24, 2026--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its profile as a profitable, self-funding biotech company with a robust, late-stage pi...